Emcure Pharmaceuticals
BSE 544210
5 stories, newest first.
- Emcure Pharmaceuticals to host Q2 FY27 earnings call for investors/analysts on November 3, 2026
- Board meeting on November 03, 2026 to approve Unaudited Results for quarter and half-year ended September 30, 2026
- Board approves draft composite scheme of amalgamation of two wholly owned subsidiaries with the holding company
- Orders imposing Rs. 57,73,96,732 aggregate penalty received from Income-tax Department
- Investor Presentation Released: FY26 Operating Revenue Crosses USD 1Bn, PAT Growth 33.1%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.